These results suggest that the tumour proliferation rate and TS status are useful markers for identifying less aggressive tumours in locally advanced NSCLCs, and that TS expression is also a useful marker to evaluate responsiveness of UFT-based chemotherapy for these tumours. The gene discussed is TYMS; the disease is neoplasm.